ArticleMolecular neurobiology2025
Protective Effects of Deinoxanthin on Brain Oxidative Damage and Gut Microbiota in the D-Galactose-Induced Aging Mice.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Deinoxanthin (DX), a special hydroxylated tetraterpenoid synthesized by Deinococcus radiodurans, exhibits robust antioxidative activities in vitro and in vivo. The accumulation of excessive reactive oxygen species (ROS) and free radicals in the body would induce brain oxidative damage, thereby contributing to the process of aging. Whether the administration of DX could protect the brain against oxidative damage in aging is of great interest. In this study, we explored the potential beneficial effects of DX on D-galactose (D-gal)-induced aging mice in vivo, particularly its protective effects on the brain against oxidative damage, and its impact on the gut microbiota of aging mice. We demonstrated that treatment with a low dose (25 mg/kg/day) and a middle dose (50 mg/kg/day) of DX could effectively alleviate motor deficits, reduce the hippocampal pathological changes, suppress microglia and astrocyte activation, and attenuate oxidative stress in D-gal-induced aging mice. However, the treatment with a high dose of DX (100 mg/kg/day) seemed to exacerbate these changes, indicating that excessive DX may exacerbate oxidative damage in aging mice. Furthermore, the administration of appropriate DX could restore the gut microbiota in aging mice, while the high dose of DX further aggravated the disturbance of the gut microbiota in aging mice. Collectively, we conclude that taking DX appropriately may be beneficial in preventing oxidative damage to the brain and improving the gut microbiota in aging mice.
Indexed as
Identifiers
40682717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.